The company is looking to develop further a line of cell therapy drugs used to treat solid tumors. CD Capital led the funding round with participation from Alwin Capital and Surplus Capital, according to a Sept. 2 Neukio news release.
“I am very grateful to all investors and to G&G Capital and Silkroad Law Firm for their support in this round of financing, and we will reward them with rapidly moving forward in the preclinical and clinical validation of our [research and development] platform and products,” said Richard Liqun Wang, PhD, founder, chair and CEO of Neukio.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
